PFS and OS. (A) PFS of subgroups divided by IGHV mutation status. (B) PFS of patients who discontinued or continued I-M after 2 years. The x-axis indicates months since the end of 2-year I-M. (C) OS of all study participants. Patients who received ibrutinib retreatment were included in the analysis of PFS and OS.